<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03279328</url>
  </required_header>
  <id_info>
    <org_study_id>1708724736</org_study_id>
    <nct_id>NCT03279328</nct_id>
  </id_info>
  <brief_title>Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents</brief_title>
  <official_title>Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed project will be an open-label, split face, randomized controlled pilot study.
      Up to 60 patients with diffuse facial actinic keratosis will be enrolled in the study. The
      purpose of this study is to understand the change in skin appearance throughout 5-FU
      treatment course and to examine whether a topical corticosteroid and moisturizer can decrease
      severity and duration of skin inflammation after 5-FU treatment course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study to understand the change in skin appearance during and after the
      course of 5-FU cream in patients with AK, and compare how the appearance of skin inflammation
      changes with the use of topical corticosteroids and moisturizers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">October 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin barrier biophysical properties</measure>
    <time_frame>2 hours</time_frame>
    <description>Transepidermal water loss (TEWL) will be measured using hand-held, noninvasive skin barrier measuring devices (Tewameter)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Topical Steroid Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One side of the face will receive a Topical Steroid ointment twice daily for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaseline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One side of the face will receive Vaseline twice daily for seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skin Barrier Moisturizer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Steroid Ointment</intervention_name>
    <description>Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.</description>
    <arm_group_label>Topical Steroid Ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vaseline</intervention_name>
    <description>Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.</description>
    <arm_group_label>Vaseline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Skin Barrier Moisturier</intervention_name>
    <description>Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.</description>
    <arm_group_label>Skin Barrier Moisturizer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female, at least 18 years of age

          -  Subject must have a diagnosis of actinic keratosis (at least 5 lesions on each side of
             the face)

          -  Able to comprehend and read the English language

        Exclusion Criteria:

          -  Subjects who do not fit the inclusion criteria

          -  Concurrently have other inflammatory skin conditions.

          -  Prior known allergy to any components to of 5FU cream, topical steroid ointment or
             vaseline.

             â€¢ Subject who, in the opinion of the investigator, will be uncooperative or unable to
             comply with study procedures (i.e.: compliant with using 5-FU cream, topical
             corticosteroid or moisturizers

          -  Those that are prisoners or cognitively impaired.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona, Banner-University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Y Shi</last_name>
      <phone>520-694-9075</phone>
      <email>vshi@email.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melisa Van Skiver</last_name>
      <phone>(520) 694-9075</phone>
      <email>melisa@email.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vivian Y Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

